Cholinergic replacement therapies have yielded little or no clinical improvement in
Alzheimer's disease (AD). Since the number of postsynaptic muscarinic receptors remains …

Molecular subtypes of muscarinic receptors (m1–m5) are novel targets for cholinergic
replacement therapies in Alzheimer's disease (AD). However, knowledge concerning the …

M1 muscarinic acetylcholine receptor (M1AchR)–G protein coupling, as measured by high-
affinity agonist binding, was examined in membranes prepared from postmortem human …

The potential usefulness of cholinergic replacement therapy for Alzheimer disease (AD) is
dependent upon retention of postsynaptic muscarinic receptors and their transduction …

In several neurodegenerative disorders, including Alzheimer's disease, a loss of the
cholinergic projections of the basal forebrain to the cerebral cortex and hippocampus …

Molecular subtypes of muscarinic receptors (m1–m5) are novel targets for cholinergic
replacement therapies in Alzheimer's disease. However, the status of these receptors in …

Previous studies examining the functional status of cortical muscarinic cholinergic M1
receptors have demonstrated an impairment in receptor-G protein coupling in Alzheimer's …

One of the consistent findings in the brains of Alzheimer's Disease (AD) patients is loss of
cholinergic function. The cholinergic approach to treatment of AD involves counteracting this …

Much evidence has clearly revealed the existence of marked cholinergic deficits in cortical
and hippocampal areas in Alzheimer's disease. Although not necessarily of etiological …

Alzheimer's disease (AD) is a common neurodegenerative disorder and a leading cause of
death among the elderly. Recent advances in our understanding of the neurobiology of AD …